QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
Positive News Sentiment  
NASDAQ:THRX

Theseus Pharmaceuticals - THRX Stock Forecast, Price & News

$13.99
+1.38 (+10.94%)
(As of 01/31/2023 05:19 PM ET)
Add
Compare
Today's Range
$11.90
▼
$14.21
50-Day Range
$4.96
▼
$12.61
52-Week Range
$4.01
▼
$15.21
Volume
441,005 shs
Average Volume
529,975 shs
Market Capitalization
$541.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.00

Theseus Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
57.3% Upside
$22.00 Price Target
Short Interest
Healthy
7.24% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$1.01 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.42) to ($1.97) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.54 out of 5 stars

Medical Sector

150th out of 1,055 stocks

Pharmaceutical Preparations Industry

64th out of 518 stocks

See Top Rated MarketRank™ Stocks Here

THRX stock logo

About Theseus Pharmaceuticals (NASDAQ:THRX) Stock

Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also develops fourth-generation EGFR inhibitor that is active against C797S, an EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

Receive THRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Theseus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

THRX Stock News Headlines

January 31, 2023 | seekingalpha.com
Theseus Pharmaceuticals: Reinventing TKIs - I'd Buy The Next Dip
January 5, 2023 | finance.yahoo.com
Theseus Pharmaceuticals Highlights Key Anticipated 2023 Milestones and Announces BCR-ABL as Target for Third Development Program
January 31, 2023 | Porter & Company (Ad)
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
December 15, 2022 | finance.yahoo.com
Investing in These 2 Biotech Stocks Could Double Your Money, Says Analyst
November 23, 2022 | finance.yahoo.com
Here's Why We're Not Too Worried About Theseus Pharmaceuticals' (NASDAQ:THRX) Cash Burn Situation
November 10, 2022 | benzinga.com
Theseus Pharmaceuticals Director Makes $1.00M Stock Purchase
November 10, 2022 | benzinga.com
Board Member of Theseus Pharmaceuticals Makes $1.00M Buy
November 3, 2022 | finance.yahoo.com
Theseus Pharmaceuticals Announces Business and Pipeline Highlights and Reports Third Quarter 2022 Financial Results
January 31, 2023 | Porter & Company (Ad)
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
October 26, 2022 | finance.yahoo.com
Theseus Pharmaceuticals Presents Preclinical Data Characterizing THE-349, its Fourth-Generation EGFR Inhibitor in Development for NSCLC, at the 34th EORTC-NCI-AACR Symposium
October 19, 2022 | finance.yahoo.com
Theseus Pharmaceuticals Appoints Steven Stein, M.D. to Board of Directors
October 3, 2022 | finance.yahoo.com
Theseus Pharmaceuticals Nominates THE-349, a Fourth-Generation EGFR Inhibitor Development Candidate in Non-Small Cell Lung Cancer
September 6, 2022 | finance.yahoo.com
Theseus Pharmaceuticals to Participate at Upcoming September Investor Conferences
September 4, 2022 | reuters.com
Theseus Pharmaceuticals Inc
August 3, 2022 | finance.yahoo.com
Theseus Pharmaceuticals to Participate Virtually in Wedbush PacGrow Healthcare Conference
July 14, 2022 | uk.finance.yahoo.com
Theseus Pharmaceuticals, Inc. (THRX)
July 1, 2022 | finance.yahoo.com
HC Wainwright Sees Over 300% Upside In This Cancer-Focused Stock
June 30, 2022 | seekingalpha.com
Theseus Pharmaceuticals initiated with a Buy at H.C. Wainwright
May 19, 2022 | finance.yahoo.com
Theseus Pharmaceuticals to Participate in Upcoming Investor Conferences
May 18, 2022 | finance.yahoo.com
Theseus Pharmaceuticals Appoints Don Hayden to Board of Directors
May 13, 2022 | seekingalpha.com
Theseus Pharmaceuticals declares $0.46 dividend
May 12, 2022 | finance.yahoo.com
Theseus Pharmaceuticals Announces Business Highlights and Reports First Quarter 2022 Financial Results
April 8, 2022 | finance.yahoo.com
Theseus Pharmaceuticals Announces Preclinical Data Characterizing Next-Generation Epidermal Growth Factor Receptor (EGFR) Inhibitors at the 2022 American Association for Cancer Research (AACR) Annual Meeting
April 7, 2022 | bizjournals.com
Clinical trial revisited
April 5, 2022 | finance.yahoo.com
Theseus Pharmaceuticals to Participate Virtually in Needham Healthcare Conference
March 10, 2022 | seekingalpha.com
Theseus Pharmaceuticals GAAP EPS of -$0.24 beats by $0.04
March 10, 2022 | finance.yahoo.com
Theseus Pharmaceuticals Announces Business Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results
See More Headlines
Receive THRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Theseus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

THRX Company Calendar

Last Earnings
11/03/2022
Today
1/31/2023
Next Earnings (Estimated)
3/09/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:THRX
CUSIP
N/A
CIK
1745020
Web
theseusrx.com
Phone
857-400-9491
Fax
N/A
Employees
26
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$22.00
High Stock Price Forecast
$22.00
Low Stock Price Forecast
$22.00
Forecasted Upside/Downside
+57.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.19)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-27,310,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-19.55%
Return on Assets
-18.84%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
27.54
Quick Ratio
27.54

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.37 per share
Price / Book
2.20

Miscellaneous

Outstanding Shares
38,710,000
Free Float
19,744,000
Market Cap
$541.55 million
Optionable
Not Optionable
Beta
2.09

Key Executives

  • Dr. Iain D. Dukes D.Phil. (Age 64)
    DPHIL, M.A., Co-Founder & Chairman
    Comp: $289.49k
  • Dr. Timothy P. Clackson Ph.D.Dr. Timothy P. Clackson Ph.D. (Age 57)
    CEO, Pres & Director
    Comp: $691.84k
  • Dr. William C. Shakespeare Ph.D. (Age 59)
    Co-Founder and Pres of R&D
    Comp: $640.59k
  • Mr. Bradford D. DahmsMr. Bradford D. Dahms (Age 33)
    Chief Financial officer
    Comp: $480.95k
  • Dr. Victor M. Rivera Ph.D. (Age 58)
    Co-Founder, Sr. VP & Chief Scientific Officer
  • Mr. Wei-Sheng Huang Ph.D.
    Co-Founder & VP of Chemistry
  • Mr. Benjamin D. Enerson
    VP of Legal Affairs
  • Dr. David P. Kerstein M.D. (Age 40)
    Chief Medical Officer
  • Dr. Nachu Narasimhan Ph.D.
    Sr. VP of Drug Metabolism & Preclinical Safety
  • Mr. Len Rozamus
    Sr. VP of Technical Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













THRX Stock - Frequently Asked Questions

Should I buy or sell Theseus Pharmaceuticals stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Theseus Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" THRX shares.
View THRX analyst ratings or view top-rated stocks.

What is Theseus Pharmaceuticals' stock price forecast for 2023?

3 brokerages have issued 12 month price objectives for Theseus Pharmaceuticals' stock. Their THRX share price forecasts range from $22.00 to $22.00. On average, they expect the company's share price to reach $22.00 in the next year. This suggests a possible upside of 65.8% from the stock's current price.
View analysts price targets for THRX or view top-rated stocks among Wall Street analysts.

How have THRX shares performed in 2023?

Theseus Pharmaceuticals' stock was trading at $4.98 at the beginning of the year. Since then, THRX stock has increased by 166.5% and is now trading at $13.27.
View the best growth stocks for 2023 here.

When is Theseus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023.
View our THRX earnings forecast.

How were Theseus Pharmaceuticals' earnings last quarter?

Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) issued its earnings results on Thursday, November, 3rd. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.34) by $0.04.

When did Theseus Pharmaceuticals IPO?

(THRX) raised $150 million in an initial public offering (IPO) on Thursday, October 7th 2021. The company issued 10,000,200 shares at $14.00-$16.00 per share.

What is Theseus Pharmaceuticals' stock symbol?

Theseus Pharmaceuticals trades on the NASDAQ under the ticker symbol "THRX."

How do I buy shares of Theseus Pharmaceuticals?

Shares of THRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Theseus Pharmaceuticals' stock price today?

One share of THRX stock can currently be purchased for approximately $13.27.

How much money does Theseus Pharmaceuticals make?

Theseus Pharmaceuticals (NASDAQ:THRX) has a market capitalization of $513.68 million. The company earns $-27,310,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis.

How can I contact Theseus Pharmaceuticals?

The official website for the company is theseusrx.com. The company can be reached via phone at 857-400-9491 or via email at christen.baglaneas@theseusrx.com.

This page (NASDAQ:THRX) was last updated on 1/31/2023 by MarketBeat.com Staff